Indietro

Eribulin mesylate as third or subsequent line chemotherapy for elderly patients

Eribulin mesylate as third or subsequent line chemotherapy for elderly patients

Eribulin mesylate as third or subsequent line chemotherapy for elderly patients with locally recurrent or metastatic breast cancer: a multicenter observational study

Eribulin mesylate as third or subsequent line chemotherapy for elderly patients

PRINCIPAL INVESTIGATOR: Dott. Vito LORUSSO

 

Data di pubblicazione:

02/10/2014

Ultimo aggiornamento:

14/01/2016